Hepatitis C stands as a significant viral infection with potentially severe consequences. Initial infection might not elicit immediate symptoms. However, without proper intervention, the virus can inflict harm upon the liver, resulting in persistent fatigue, an elevated risk of diabetes, and other concurrent medical ailments. Fortunately, for a considerable number of individuals, hepatitis C can be effectively managed and resolved through a treatment regimen lasting eight to twelve weeks, involving the administration of specific medications.
Several years ago, the federal government approved a new class of drugs called direct-acting antivirals (DAAs) to treat hepatitis C. These drugs can help many people, regardless of how long they’ve had the virus or the damage it has caused.
As of January 1, 2023, Texas Medicaid has designated the medication Mavyret (glecaprevir/pibrentasvir) as the preferred course of DAA treatment for beneficiaries. AbbVie, the manufacturer of Mavyret, has entered into a partnership with the Texas Health and Human Services Commission, with the collective goal of diminishing the prevalence of hepatitis C within the state.
Mavyret is available through prescription and serves as a therapeutic option for both adults and children aged 3 and above, affected by chronic hepatitis C. Typically, the treatment regimen spans eight weeks, but its duration can be extended based on the recommendation of your healthcare provider. Providers hold the authority to prescribe Mavyret for the complete duration of the treatment, alleviating the need for refill requests.
Individuals grappling with hepatitis C, who are enlisted in the Texas Medicaid program, are encouraged to engage in a discussion with their healthcare provider to determine the suitability of DAA treatment utilizing Mavyret.
Next steps for Providers:
Providers should share this communication with their staff.
Community First Resources:
Email ProviderRelations@cfhp.com or call 210-358-6294.